PD-L1, MMR, and EGFR expression in gastrointestinal neuroendocrine tumors

Sevil Karabağ; Meltem Öznur

Makale detayları

PD-L1, MMR, and EGFR expression in gastrointestinal neuroendocrine tumors

Yazarlar:

Sevil Karabağ | Meltem Öznur

Yayıncı:

Cukurova University

Ana Başlıklar:

Patoloji

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.400-406

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320798

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: There are limited studies on gastrointestinal neuroendocrine tumors NETs in the literature. This study aimed to determine PD-L1 and EGFR expression in primary G1 and G2 NETs and neuroendocrine carcinoma located in the gastrointestinal system, explore the relationship between grades, and investigate the loss of DNA mismatch repair MMR protein expression and its association with PD-L1 expression. Materials and Methods: All patients diagnosed with primary gastrointestinal NETs between January 2017 and January 2021 were included in this study. The study evaluated the protein expression of PD-L1, EGFR, MLH1, MSH2, MSH6, and PMS2 by immunohistochemistry. A total of 30 patients were included in the study. Results: PD-L1 expression was detected in tumor cells andor tumor microenvironment immune cells in 8 cases 28, consisting of four G1, two G2, and two NEC cases. There was no significant relationship between histological grade and PD-L1 expression. A loss of expression of at least one MMR protein was noted in 16 cases 53. A loss of MMR protein expression was detected in five of the eight cases with PD-L1 expression. EGFR expression was not detected in any of the cases. Conclusion: The study revealed a loss of MMR protein expression in 53 and PD-L1 expression in 27 of gastrointestinal NETs. This study might be a pioneer for future studies on immune checkpoint inhibitors in microsatellite-unstable NETs, thereby contributing to providing a treatment alternative for this group of patients.

 Purpose: There are limited studies on gastrointestinal neuroendocrine tumors NETs in the literature. This study aimed to determine PD-L1 and EGFR expression in primary G1 and G2 NETs and neuroendocrine carcinoma located in the gastrointestinal system, explore the relationship between grades, and investigate the loss of DNA mismatch repair MMR protein expression and its association with PD-L1 expression. Materials and Methods: All patients diagnosed with primary gastrointestinal NETs between January 2017 and January 2021 were included in this study. The study evaluated the protein expression of PD-L1, EGFR, MLH1, MSH2, MSH6, and PMS2 by immunohistochemistry. A total of 30 patients were included in the study. Results: PD-L1 expression was detected in tumor cells andor tumor microenvironment immune cells in 8 cases 28, consisting of four G1, two G2, and two NEC cases. There was no significant relationship between histological grade and PD-L1 expression. A loss of expression of at least one MMR protein was noted in 16 cases 53. A loss of MMR protein expression was detected in five of the eight cases with PD-L1 expression. EGFR expression was not detected in any of the cases. Conclusion: The study revealed a loss of MMR protein expression in 53 and PD-L1 expression in 27 of gastrointestinal NETs. This study might be a pioneer for future studies on immune checkpoint inhibitors in microsatellite-unstable NETs, thereby contributing to providing a treatment alternative for this group of patients.

 Purpose: There are limited studies on gastrointestinal neuroendocrine tumors NETs in the literature. This study aimed to determine PD-L1 and EGFR expression in primary G1 and G2 NETs and neuroendocrine carcinoma located in the gastrointestinal system, explore the relationship between grades, and investigate the loss of DNA mismatch repair MMR protein expression and its association with PD-L1 expression. Materials and Methods: All patients diagnosed with primary gastrointestinal NETs between January 2017 and January 2021 were included in this study. The study evaluated the protein expression of PD-L1, EGFR, MLH1, MSH2, MSH6, and PMS2 by immunohistochemistry. A total of 30 patients were included in the study. Results: PD-L1 expression was detected in tumor cells andor tumor microenvironment immune cells in 8 cases 28, consisting of four G1, two G2, and two NEC cases. There was no significant relationship between histological grade and PD-L1 expression. A loss of expression of at least one MMR protein was noted in 16 cases 53. A loss of MMR protein expression was detected in five of the eight cases with PD-L1 expression. EGFR expression was not detected in any of the cases. Conclusion: The study revealed a loss of MMR protein expression in 53 and PD-L1 expression in 27 of gastrointestinal NETs. This study might be a pioneer for future studies on immune checkpoint inhibitors in microsatellite-unstable NETs, thereby contributing to providing a treatment alternative for this group of patients.

 Amaç: Literatürde gastrointestinal nöroendokrin tümörlerle NET ilgili kısıtlı çalışma bulunmaktadır. Bu çalışmada gastrointestinal sistem yerleşimli G1, G2 ve G3 nöroendokrin tümörlerde PD-L1 ve EGFR ekspresyonunu saptamak, gradeler arasındaki ilişkiyi incelemek, MMR protein kaybını ve bunun PD-L1 ile ilişkisini araştırmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya Ocak 2017 ile Ocak 2021 tarihleri arasında primer gastrointestinal NET tanısı konulan tüm hastalar dahil edildi. PD-L1, EGFR, MLH1, MSH2, MSH6 ve PMS2yi immünohistokimya ile değerlendirdik. Çalışmaya toplam 30 hasta dahil edildi. Bulgular: Olgular mide, pankreas, kolon, apendiks ve karaciğer yerleşimli idi. Olguların 14 47 G1, 723 si G2, 9 30 u G3 nöroendokrin tümördü. Tümör veveya tümör mikroçevresi immün hücrelerdeTMIC G1 dört, G2 iki, G3 iki olguda olmak üzere toplam 8 olguda 28 PD-L1 ekspresyonu saptandı. Histolojik grade ile PD-L1 ekspresyonu arasında anlamlı ilişki saptanmadı. Olguların 16sında 53 en az bir MMR ekspresyonunda kayıp izlendi. PD-L1 ekspresyonu olan 8 olgunun beşinde MMR kaybı saptandı, üçünde izlenmedi. Hiçbir olguda EGFR ekspresyonu saptanmadı. Sonuç: Gastrointestinal NETlerin 53ünde MMR protein kaybı ve 27sinde PD-L1 ekspresyonu gözlemledik. Çalışmamızın, Mikrosatellit instable NETlerde bir tedavi alternatifi olabilecek immün kontrol noktası inhibitörleri ile ilgili gelecekteki çalışmalara öncü olabileceğini düşünmekteyiz.

Makale detayları

PD-L1, MMR, and EGFR expression in gastrointestinal neuroendocrine tumors

Yazarlar:

Sevil Karabağ | Meltem Öznur

Yayıncı:

Cukurova University

Ana Başlıklar:

Patoloji

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.400-406

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320798

pISSN:

2602-3032

Neuroendocrin tumors

PD-L1

MMR

EGFR

immunohistochemistryNöroendokrin tümör

PD-L1

MMR

EGFR

immunohistokimya

Sayı

Makale detayları

Yazarlar: Sevil Karabağ | Meltem Öznur

Yayıncı: Cukurova University

Ana Başlıklar: Patoloji

Dergi: Cukurova Medical Journal Vol.49 Issue 2, pp.400-406

Belge Tipi: Makale

Yayın Tarihi: 6/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001320798

pISSN: 2602-3032

Sayı

Yazarlar:

Sevil Karabağ | Meltem Öznur

Yayıncı:

Cukurova University

Ana Başlıklar:

Patoloji

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.400-406

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320798

pISSN:

2602-3032